We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Read MoreHide Full Article
Key Takeaways
IONS gained 5.6% after the FDA gave Breakthrough Therapy status to ION582 for Angelman syndrome.
The designation followed phase I/II HALOS data showing broad functional gains and good safety.
IONS has begun the phase III REVEAL study for ION582 in children and adults with Angelman syndrome.
Ionis Pharmaceuticals (IONS - Free Report) announced that the FDA has granted the Breakthrough Therapy designation to its pipeline candidate, ION582, for the treatment of Angelman syndrome (AS), a rare neurological disease.
Shares of Ionis were up 5.6% yesterday, following the announcement of the news.
AS is a rare neurogenetic disorder that impacts around 1 in 21,000 people globally. The disease often presents in infancy, which leads to severe developmental challenges, including cognitive and motor impairments, speech loss, balance issues, seizures, anxiety and sleep disturbances, taking a severe toll on the quality of life. Currently, no disease-modifying therapies are approved for treating AS.
Year to date, shares of Ionis have surged 84.2% compared with the industry’s rise of 12.5%.
Image Source: Zacks Investment Research
How Does the FDA's Breakthrough Tag Benefit Ionis?
The FDA’s Breakthrough Therapy designation speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests the drug may significantly improve over existing treatments on one or more important clinical measures. Drug/candidates with this designation receive more intensive guidance and organizational support from the FDA authorities.
The FDA’s Breakthrough Therapy tag to ION582 was based on data from the phase I/II HALOS study, which evaluated ION582 for treating AS. Data from the same showed that treatment with ION582 led to consistent and encouraging clinical improvement across all AS functional domains, including communication, cognition and motor function, while demonstrating a favorable safety and tolerability.
Earlier this year, Ionis initiated the phase III REVEAL study evaluating ION582 for treating children and adults with AS.
The FDA previously granted an Orphan Drug designation, Fast Track designation and Rare Pediatric designations to ION582 for treating AS.
Ultragenyx Pharmaceuticals (RARE - Free Report) is also developing its pipeline candidate, GTX-102 (apazunersen), to treat AS.
In June, the FDA granted a Breakthrough Therapy designation to RARE’s GTX-102 for treating AS. Ultragenyx has completed enrollment and is currently dosing patients in the phase III Aspire study evaluating GTX-102 for treating patients with AS.
With both ION582 and GTX-102 in phase III development for AS, it remains to be seen which will succeed in gaining the first FDA approval for this rare disorder.
In the past 60 days, estimates for Akero Therapeutics’ 2025 loss per share have narrowed from $3.93 to $3.82. Loss per share estimates for 2026 have narrowed from $4.27 to $4.12 during the same period. AKRO stock has surged 60.4% year to date.
Akero Therapeutics’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 49.24%.
In the past 60 days, estimates for Adaptive Biotechnologies’ 2025 loss per share have narrowed from 87 cents to 71 cents. Loss per share estimates for 2026 have narrowed from 65 cents to 60 cents during the same period. ADPT stock has soared 110.3% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, the average surprise being 23.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Key Takeaways
Ionis Pharmaceuticals (IONS - Free Report) announced that the FDA has granted the Breakthrough Therapy designation to its pipeline candidate, ION582, for the treatment of Angelman syndrome (AS), a rare neurological disease.
Shares of Ionis were up 5.6% yesterday, following the announcement of the news.
AS is a rare neurogenetic disorder that impacts around 1 in 21,000 people globally. The disease often presents in infancy, which leads to severe developmental challenges, including cognitive and motor impairments, speech loss, balance issues, seizures, anxiety and sleep disturbances, taking a severe toll on the quality of life. Currently, no disease-modifying therapies are approved for treating AS.
Year to date, shares of Ionis have surged 84.2% compared with the industry’s rise of 12.5%.
Image Source: Zacks Investment Research
How Does the FDA's Breakthrough Tag Benefit Ionis?
The FDA’s Breakthrough Therapy designation speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests the drug may significantly improve over existing treatments on one or more important clinical measures. Drug/candidates with this designation receive more intensive guidance and organizational support from the FDA authorities.
The FDA’s Breakthrough Therapy tag to ION582 was based on data from the phase I/II HALOS study, which evaluated ION582 for treating AS. Data from the same showed that treatment with ION582 led to consistent and encouraging clinical improvement across all AS functional domains, including communication, cognition and motor function, while demonstrating a favorable safety and tolerability.
Earlier this year, Ionis initiated the phase III REVEAL study evaluating ION582 for treating children and adults with AS.
The FDA previously granted an Orphan Drug designation, Fast Track designation and Rare Pediatric designations to ION582 for treating AS.
Ultragenyx Pharmaceuticals (RARE - Free Report) is also developing its pipeline candidate, GTX-102 (apazunersen), to treat AS.
In June, the FDA granted a Breakthrough Therapy designation to RARE’s GTX-102 for treating AS. Ultragenyx has completed enrollment and is currently dosing patients in the phase III Aspire study evaluating GTX-102 for treating patients with AS.
With both ION582 and GTX-102 in phase III development for AS, it remains to be seen which will succeed in gaining the first FDA approval for this rare disorder.
Ionis Pharmaceuticals, Inc. Price
Ionis Pharmaceuticals, Inc. price | Ionis Pharmaceuticals, Inc. Quote
IONS' Zacks Rank & Stocks to Consider
Ionis currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Akero Therapeutics’ 2025 loss per share have narrowed from $3.93 to $3.82. Loss per share estimates for 2026 have narrowed from $4.27 to $4.12 during the same period. AKRO stock has surged 60.4% year to date.
Akero Therapeutics’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 49.24%.
In the past 60 days, estimates for Adaptive Biotechnologies’ 2025 loss per share have narrowed from 87 cents to 71 cents. Loss per share estimates for 2026 have narrowed from 65 cents to 60 cents during the same period. ADPT stock has soared 110.3% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, the average surprise being 23.99%.